Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma.-论文-万方医学网

第一作者： Frederick L,Locke

第一单位： Department of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL 33612, USA. Electronic address: frederick.locke@moffitt.org.

作者： Frederick L,Locke ^[1] ; Sattva S,Neelapu ^[2] ; Nancy L,Bartlett ^[3] ; Tanya,Siddiqi ^[4] ; Julio C,Chavez ^[5] ; Chitra M,Hosing ^[6] ; Armin,Ghobadi ^[3] ; Lihua E,Budde ^[4] ; Adrian,Bot ^[7] ; John M,Rossi ^[7] ; Yizhou,Jiang ^[7] ; Allen X,Xue ^[7] ; Meg,Elias ^[7] ; Jeff,Aycock ^[7] ; Jeff,Wiezorek ^[7] ; William Y,Go ^[7]

作者单位： Department of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL 33612, USA. Electronic address: frederick.locke@moffitt.org. ^[1] Division of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. ^[2] Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO 63110, USA. ^[3] Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA 91010, USA. ^[4] Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL 33612, USA. ^[5] Division of Cancer Medicine, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. ^[6] Kite Pharma, Santa Monica, CA 90404, USA. ^[7]

主题词成年人(Adult);老年人(Aged);抗原, CD19(Antigens, CD19);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);综合疗法(Combined Modality Therapy);疾病恶化(Disease Progression);抗药性, 肿瘤(Drug Resistance, Neoplasm);女(雌)性(Female);随访研究(Follow-Up Studies);人类(Humans);免疫表型分型(Immunophenotyping);免疫疗法, 过继(Immunotherapy, Adoptive);淋巴瘤, 大B细胞, 弥漫性(Lymphoma, Large B-Cell, Diffuse);淋巴瘤, 非霍奇金(Lymphoma, Non-Hodgkin);男(雄)性(Male);中年人(Middle Aged);肿瘤分期(Neoplasm Staging);受体CD3复合物, 抗原, T细胞(Receptor-CD3 Complex, Antigen, T-Cell);重组融合蛋白质类(Recombinant Fusion Proteins);T淋巴细胞(T-Lymphocytes);治疗结果(Treatment Outcome)

DOI 10.1016/j.ymthe.2016.10.020

PMID 28129122

发布时间 2024-03-26

检索历史清除

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma.

Molecular therapy

相似文献

Molecular therapy

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma.

Molecular therapy

相似文献

Molecular therapy

相关期刊

检索历史清除